explore -WSS

explore

author：fashion 2025-09-30 15:15:52 - browse：36

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Bernie Sanders bashes nonprofit hospitals over their tax breaks

WSS

STAT Readout: Today's biotech news includes Sana and Amylyx

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

'Null' research findings aren't empty of meaning. Let's publish them

CDC recommends RSV monoclonal antibody for infants

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

How doctors and nurses shape Google's AI

hotspot

explore

hotspot

Continuity nursing helped my family in our darkest PICU moments

Late stage cancers on the rise after pandemic delayed screenings

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

There’s no way to know how good AI health technologies are

Psychedelics group wrestles with new pharma identity

Flint parents haunted by uncertainty, fears of lead poisoning

Wildfire smoke exposes gaps in outdoor worker protections

Chris Christie meets with Zelenskyy during Ukraine trip

Continuity nursing helped my family in our darkest PICU moments

There’s no way to know how good AI health technologies are

focus

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Readout LOUD podcast: Merger Mondays, Ozempic panic

Pharma showers House GOP doctor with campaign cash

STAT Readout Newsletter: Today in biotech, life science news

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Physicians aren't 'burning out.' They're suffering from moral injury

entertainment

Wikipedia

entertainment

focus